Javelin DLBCL: This phase III trial is evaluating three Avelumab (immunotherapy)-based combination regimens for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)Phase 1b/Phase 3 Multicenter Study Of Avelumab (msb0010718c) In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, Cd20 Antagonist And/or Conventional Chemotherapy In Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma (Dlbcl) Javelin Dlbcl

Inclusion

-Any of the following as defined by the WHO, 2016 lymphoid neoplasm classifications and histologically confirmed:

• Diffuse large B-cell lymphoma (DLBCL), Not Otherwise Specified (NOS): Germinal center B-cell type (GCB), Activated B-cell type (ABC)
• High-grade B-cell lymphoma (HGBCL) NOS
• HGBCL with MYC and BCL2 and/or BCL6 rearrangements
• T-cell histocyte-rich large B-cell lymphoma
• EBV+ DLBCL, NOS
• HHV8+ DLBCL, NOS

Relapsed or refractory disease following at least 2 lines (and a maximum of 4 lines) of prior rituximab containing multi-agent chemotherapy which may include an autologous stem cell transplantation unless patients are not considered suitable for intensive second-line chemotherapy or autologous stem cell transplantation. Patients who are ineligible for intensive second line chemotherapy,must have received at least one prior rituximab-containing combination chemotherapy regimen. Patients who are ineligible for intensive second line chemotherapy, must have received at least one prior rituximab-containing combination chemotherapy regimen.

• Baseline measurable disease with at least 1 bi dimensional lesion with longest diameter (LDi) >1.5cm on CT scan which is FDG avid on PET scan.
• A biopsy (archived or Screening/recent) will be collected at Screening.
• At least 18years of age (or ≥20 years in Japan).
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.